Kiener Peter A
Known title: DirectorCIK: 0001328146
Associated companies
Transaction History
| CUE | ▲ Buy | Option Exercise | 9,682 | $28K | 3/23/2023 | View on chart |
| CUE | ▼ Sell | Open Market | 9,325 | $31K | 3/23/2023 | View on chart |
| CUE | ▲ Buy | Option Exercise | 1,361 | $4K | 11/16/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 1,361 | $25K | 11/16/2021 | View on chart |
| CUE | ▲ Buy | Option Exercise | 18,815 | $54K | 11/15/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 18,815 | $337K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.